Brazil’s health plans may be the hidden winners of the GLP-1 boom
Patients still pay for the drugs, while health plans mainly cover the consultations and tests around them.
Patients still pay for the drugs, while health plans mainly cover the consultations and tests around them.
Industry associations representing multinational and domestic drugmakers say patent flexibility could hurt investment and innovation.